LUND (SWEDEN) – Immunovia will participate in the Cowen 42nd Annual Health Care Virtual Conference on March 9, 2022.
Philipp Mathieu, Acting CEO and President, is scheduled to present on Wednesday, March 9, 2022 at 10:30 am ET (16:30 pm CET).
Link to the webcast: https://wsw.com/webcast/cowen108/register.aspx?conf=cowen108&page=immnov&url=https://wsw.com/webcast/cowen108/immnov/2375982
A replay will be available on the Company’s website following the event at www.immunovia.com.
For more information, please contact:
Senior Director Investor Relations and Corporate Communications
Tel: +46 736 36 35 74
The information was submitted for publication on 22 February 2022, at 09:30 am CET.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Press release (PDF)